Cellectis Unveils Gene Switch That Edits Expression, Not DNA Itself

NEW YORK, NY – April 27, 2026 – Biotechnology firm Cellectis today announced a significant advance in genetic medicine, presenting a new platform that can switch disease-related genes off without making a single cut to the DNA sequence. The research, unveiled at the American Society of Gene and Cell Therapy (ASGCT) annual meeting, details an epigenetic editing approach that offers a potentially safer alternative to traditional gene editing tools, marking a pivotal step in the quest for more precise and less invasive therapies.

The company's platform, built on engineered proteins called TALE-based epigenetic modulators (TALEM), functions like a highly specific dimmer switch for genes. Instead of rewriting the genetic code, it modifies the "epigenome"—the layer of chemical instructions that tells genes when to be active or silent. This "no-cut" method sidesteps many of the core safety concerns associated with permanent DNA alterations, opening a new frontier for treating a range of human diseases.

A 'Gentle' Revolution in Gene Therapy

For years, the promise of gene therapy has been dominated by tools like CRISPR-Cas9, which act like molecular scissors to cut and paste DNA. While revolutionary, this approach carries inherent risks. The act of creating double-strand breaks in DNA can lead to unintended and permanent off-target mutations or large-scale genomic instability, concerns that have made regulators and scientists cautious.

Epigenetic editing represents a paradigm shift. Rather than altering the foundational blueprint of life, it manipulates the cellular machinery that reads it. The human body naturally uses epigenetic marks, such as DNA methylation and histone modifications, to control gene expression in different cells. Cellectis's TALEM technology hijacks this natural process. The engineered proteins are designed with a DNA-binding domain (the TALE) that guides them to a precise location on a chromosome, and a functional domain that then applies an epigenetic "off" signal. This silences the target gene without damaging the DNA itself.

The primary advantage of this method is its potential for an improved safety profile. By avoiding DNA breaks, the risk of mutagenesis is significantly reduced. Furthermore, because epigenetic changes are, in principle, reversible, it raises the possibility of treatments that could be modulated or even undone if necessary—a feature entirely absent from permanent gene editing. This "gentle" approach could broaden the therapeutic window for genetic medicines, making them applicable to a wider array of conditions where simply dialing down a gene's activity is sufficient.

From High-Throughput Screening to High-Impact Results

The data presented by Cellectis at the ASGCT meeting provides a compelling proof-of-concept for the power and precision of its platform. A key innovation behind the results is a high-throughput screening system the company developed to rapidly build and test hundreds of TALEM combinations, allowing researchers to quickly identify the most potent molecular tools for any given gene.

Using this system, Cellectis targeted two distinct and therapeutically relevant genes. The first is a gene highly active in hepatocytes, or liver cells, a critical target for hundreds of genetic disorders that currently have few effective treatments beyond transplantation. The second target is a gene implicated in T-cell dysfunction and exhaustion. This is a major obstacle in cancer immunotherapy, where CAR T-cells, a type of engineered immune cell, can lose their effectiveness over time as they battle tumors.

In both cell types, the results were striking. The TALEM platform achieved a greater than 90% reduction in the activity of the target genes. Crucially, this gene knockdown was not transient; the effect remained stable throughout the duration of the study, demonstrating the durability of the epigenetic modifications.

“We are excited to present these results at ASGCT, which demonstrate Cellectis’ ability to apply its gene editing platform into the emerging field of epigenetic editing,” said Louisa Mayer, Ph.D., Scientist II and Supervisor - Innovation & Gene Editing at Cellectis. “This work shows our ability to design and identify highly potent epigenetic editors across different cell types, thereby enriching our gene‑editing toolbox.”

Navigating a Competitive Epigenetic Landscape

Cellectis is not alone in recognizing the immense potential of dialing genes up or down. The field of epigenetic editing is quickly becoming a hotbed of innovation and investment, with several well-funded companies vying to establish dominance. Competitors like nChroma Bio (the result of a recent merger between Chroma Medicine and Nvelop Therapeutics), Tune Therapeutics, and Epic Bio are all developing platforms to control gene expression without altering the DNA sequence.

Many of these rivals have built their platforms around a modified version of CRISPR known as dCas9, or "dead" Cas9, which can guide epigenetic modifiers to a target but lacks the ability to cut DNA. Cellectis's choice to use TALE-based effectors represents a distinct technological strategy. TALE proteins are another class of programmable DNA-binding molecules that offer their own set of characteristics regarding specificity and delivery. By advancing its TALEM platform, Cellectis is not only expanding its internal capabilities beyond its well-known allogeneic CAR T-cell therapies but also diversifying its technological toolkit in a rapidly evolving market.

The global epigenetics market is projected to grow substantially, with some analysts forecasting it to exceed $50 billion by the early 2030s. The cancer epigenetics therapy market alone is expected to expand at a rapid pace, driven by the need for novel treatments that can overcome resistance and improve patient outcomes. Cellectis's successful demonstration in T-cells positions it to directly address a key unmet need within the lucrative cancer immunotherapy space.

The Path Forward: Promise and Hurdles

The journey from a promising poster presentation to a life-saving therapy is long and fraught with challenges. While the "no-cut" approach may offer a smoother regulatory path by mitigating some of the most serious safety concerns of gene editing, epigenetic therapies will still face intense scrutiny. Regulators at the FDA and EMA will require extensive data demonstrating not only efficacy but also the absence of unintended epigenetic off-target effects. Ensuring that these molecular switches only affect their intended target and don't accidentally silence essential genes elsewhere in the genome will be paramount.

Furthermore, like all gene-based medicines, efficient delivery remains a significant hurdle. Getting the large TALEM protein machinery into the right cells within the human body, whether in the liver or in circulating T-cells, requires sophisticated and reliable delivery vehicles.

Despite these challenges, the work presented by Cellectis represents a clear and powerful signal. The ability to achieve stable, potent, and specific gene silencing without the risks of permanent DNA modification could fundamentally reshape the landscape of genetic medicine. This technology holds the promise of creating more controllable and potentially safer treatments for a vast spectrum of diseases, from rare genetic liver disorders to the most common forms of cancer. As this technology matures, it moves the entire field one step closer to the ultimate goal of precision medicine: delivering the right intervention, to the right gene, at the right time.